Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05828823
Other study ID # IRB00092986
Secondary ID CER-2022C1-26300
Status Recruiting
Phase N/A
First received
Last updated
Start date February 26, 2024
Est. completion date March 2028

Study information

Verified date November 2023
Source Wake Forest University Health Sciences
Contact Denisse A Funes
Phone 336-716-8671
Email dfunes@wakehealth.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function. The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.


Description:

This study will analyze the effects of differentiated care with individualized hemodialysis on patient health related quality of life, fatigue, employment, and caregiver burden in patients with Kidney dysfunction requiring dialysis (KDRD) and appreciable kidney function. This study will compare the outcomes in survival, hospitalization, preservation of the kidney function and quality of life between hemodialysis tailored to each patient needs (incremental) and conventional hemodialysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 350
Est. completion date March 2028
Est. primary completion date September 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Patient eligibility Criteria: Inclusion Criteria: - Clinical Inclusion Criteria: - Age = 18 years - Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 6 weeks - Has received =18 sessions of intermittent HD (i.e., on HD for =6 weeks) at the time patient is approached for potential study participation Residual Kidney Function Inclusion Criteria: - Kidney urea clearance# =3.5 mL/min/1.73 m2 - Urine volume# of =500 mL/24 h Exclusion Criteria: - Pre-HD serum K =5.8 mEq/L, Na =125 mEq/L, or bicarbonate level =17 mEq/L - Requirement or anticipated requirement of high-volume ultrafiltration - Unable or unwilling to follow the study protocol for any reason - Known pregnancy or planning to attempt to become pregnant or lactating women - Estimated survival or dialysis modality change or center transfer <6 months Caregiver Eligibility Criteria: - be at least 18 years old - be the main caregiver (at patient's choice) - be a close relative of the patient (spouse, child, sibling, parent, grandchild) - have no known psychiatric and neurologic disorders (through direct inquiry from the person) - not be a member of the medical or healthcare team - not be the caregiver for another patient with chronic illness - not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)

Study Design


Intervention

Device:
Hemodialysis twice weekly
Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
Other:
Hemodialysis thrice weekly
Conventional hemodialysis regimen

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States Johns Hopkins University School of Medicine (JHUSM) Baltimore Maryland
United States University of North Carolina Chapel Hill Chapel Hill North Carolina
United States University of Virginia (UVA) Charlottesville Virginia
United States Cleveland Clinic, Case Western Reserve University (CWRU) Cleveland Ohio
United States University of Florida Jacksonville Florida
United States Renal Research Institute (RRI) New York New York
United States Atrium Health Wake Forest Baptist Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences Patient-Centered Outcomes Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Characterize implementation processes using mixed methods - Intervention characteristics Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - External factors that mediate implementation Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - Adoption Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - Reach Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Other Characterize implementation processes using mixed methods - Sustainability, to assess barriers and facilitators to maintaining intervention Process evaluation will include a) Intervention characteristics, to assess organizational readiness to change, intervention acceptability and appropriateness; b) Inner setting characteristics, to assess barriers and facilitators to the adoption of HD intervention at the partnering organizations; c) External factors that mediate implementation; d) Adoption; e) Reach; f) Fidelity, to assess adherence to serial timed urine collection and HD treatment schedule; and g) Sustainability, to assess barriers and facilitators to maintaining intervention 2 years
Primary Number of Clinical events of safety composite of all-cause Emergency Department visits, hospitalizations, or death year 2
Secondary EuroQOL-5D-5L scores Health-related quality of life Health-related quality of life and residual kidney function Compare the effects of CMIHD and CHD - The descriptive system covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with 5 levels of severity in each dimension (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems - Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. year 2
Secondary Trail Making Test B scores Health-related quality of life Health-related quality of life and residual kidney function Patient participants' cognitive function will be assessed using change in Trail Making Test B score - The Trail Making Test measures your visual attention, mental flexibility, processing speed, and motor speed based on how quickly and accurately you connect dots in ascending order (either numerically or with alternating numbers and letters). The test can be used to diagnose dementia and other cognitive disorders - Higher scores indicate a higher degree of cognitive impairment Baseline and months 6, 12, 18, & 24
Secondary Standardized Outcomes in Nephrology (SONG) scores Health-related quality of life Health-related quality of life and residual kidney function SONG-HD Fatigue score - The SONG-HD Fatigue measure consists of three items that assess (1) the effect of fatigue on life participation, (2) tiredness, and (3) level of energy. These dimensions are assessed on a four-point Likert scale indicating increasing severity, ranging from zero (not at all) to three (severely). Higher scores meaning higher severity Baseline and months 6, 12, 18, & 24
Secondary Time to recover from hemodialysis (HD) Health-related quality of life Health-related quality of life and residual kidney function Patient-reported functional status and fatigue will be assessed using Time to recover from HD Baseline and monthly up to 2 years
Secondary Caregiver burden Zarit Caregiver Burden Scores Health-related quality of life Health-related quality of life and residual kidney function Caregiver burden will be assessed using the Zarit Caregiver Burden Scale - The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. 9. Higher scores indicate greater burden. A score of 17 or more was considered high burden. Baseline, months 6, 12, 18, & 24
Secondary Change in urine output Urine collections will be analyzed at the lab used by the dialysis center Baseline, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, and Year 2
Secondary Change in kidney urea clearance (mL/min/1.73 m2) Urine collections will be analyzed at the lab used by the dialysis center Baseline, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, and Year 2
Secondary Change in kidney creatinine clearance (mL/min/1.73 m2) Urine collections will be analyzed at the lab used by the dialysis center Baseline, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, and Year 2
Secondary Hospital free days per 100 patient-days The duration of hospital-free days will be determined for each patient and calculated in the whole cohort per 100 patient-days. It is anticipated an array of hospitalization events for each participant, ranging from no hospitalization to frequent hospitalizations per study period. All periods of hospitalization, per each participant, will be analyzed. A period of hospitalization will be computed from date of hospital admission to the date of discharge. Hospital-free days may include one or more discrete time segments of non-hospitalization between periods hospitalization. The total hospital-free days per patient participant will be calculated as total study days - hospitalization days. Hospital-free days will be normalized per 100 patient-days. year 2
Secondary Illness Intrusiveness Rating Scale Patients will rate the degree of interference caused by HD treatments on the following domains: health, diet, work, active and passive recreation, financial situation, relationship with spouse, sex life, family and other social relations, self-expression/self- improvement, religious expression, and community/civic involvement. Individual item ratings and the sum across ratings will be recorded. The total scale has a range of 13 (minimum intrusiveness) to 91 (extreme intrusiveness). Assessed at baseline and monthly up to 2 years
Secondary Employment status The employment status for patients and caregivers will be assessed through surveys. Baseline and months 6, 12, 18 and 24
See also
  Status Clinical Trial Phase
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Completed NCT03582592 - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis N/A
Completed NCT02694068 - Biological Determinants of Peritoneal Dialysis
Not yet recruiting NCT02832505 - Applications of MRI in Kidney Disease
Not yet recruiting NCT02590081 - Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Phase 4
Completed NCT01859884 - Optimizing Kidney Transplant Informed Consent N/A
Completed NCT00509236 - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) Phase 3
Completed NCT02009514 - Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients Phase 4
Not yet recruiting NCT06377293 - Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients N/A
Completed NCT01528800 - Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients Phase 2
Completed NCT01863914 - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Phase 2
Withdrawn NCT06030050 - Animal Assisted Intervention for Hemodialysis Outpatients N/A
Completed NCT04610593 - Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis N/A
Recruiting NCT05931276 - CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes Phase 3
Completed NCT00143741 - Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers Phase 1
Active, not recruiting NCT02755610 - Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis N/A
Recruiting NCT03142529 - Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease Phase 1/Phase 2
Completed NCT02342119 - Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation N/A
Recruiting NCT05614115 - Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD Phase 1